Abstract
A series of novel (±) 3-menthone semicarbazides (1-7) and thiosemicarbazides (8-14) were synthesized using an appropriate synthetic route and characterized by thin layer chromatography and spectral analysis. The anticonvulsant activity of synthesized compounds was established after intraperitoneal administration in three seizure models in mice which include maximal electroshock seizure (MES), subcutaneous pentylene tetrazole (scPTZ) induced seizure and minimal neurotoxicity test. Seven compounds exhibited protection in both models and N1 – (4-fluorophenyl) – N4- (menth-3- one) semicarbazide (4) emerged as the most active compound with MES ED50 of 44.15mg/kg and scPTZ ED50 of 38.68mg/kg at 0.25h duration. These compounds were found to elevate γ-amino butyric acid (GABA) levels in the midbrain region, thus indicating that (±) 3-menthone semicarbazides could be considered as a lead molecule in designing of a potent anticonvulsant drug.
Keywords: (±) 3-menthone, semicarbazides, thiosemicarbazides, anticonvulsant, Maximal Electroshock Seizure (MES), subcutaneous pentylene tetrazole (scPTZ), Antiepileptic drug development (AED)
Medicinal Chemistry
Title: Menthone Semicarbazides and Thiosemicarbazides as Anticonvulsant Agents
Volume: 6 Issue: 1
Author(s): Jainendra Jain, Y. Kumar, James Stables and Reema Sinha
Affiliation:
Keywords: (±) 3-menthone, semicarbazides, thiosemicarbazides, anticonvulsant, Maximal Electroshock Seizure (MES), subcutaneous pentylene tetrazole (scPTZ), Antiepileptic drug development (AED)
Abstract: A series of novel (±) 3-menthone semicarbazides (1-7) and thiosemicarbazides (8-14) were synthesized using an appropriate synthetic route and characterized by thin layer chromatography and spectral analysis. The anticonvulsant activity of synthesized compounds was established after intraperitoneal administration in three seizure models in mice which include maximal electroshock seizure (MES), subcutaneous pentylene tetrazole (scPTZ) induced seizure and minimal neurotoxicity test. Seven compounds exhibited protection in both models and N1 – (4-fluorophenyl) – N4- (menth-3- one) semicarbazide (4) emerged as the most active compound with MES ED50 of 44.15mg/kg and scPTZ ED50 of 38.68mg/kg at 0.25h duration. These compounds were found to elevate γ-amino butyric acid (GABA) levels in the midbrain region, thus indicating that (±) 3-menthone semicarbazides could be considered as a lead molecule in designing of a potent anticonvulsant drug.
Export Options
About this article
Cite this article as:
Jain Jainendra, Kumar Y., Stables James and Sinha Reema, Menthone Semicarbazides and Thiosemicarbazides as Anticonvulsant Agents, Medicinal Chemistry 2010; 6 (1) . https://dx.doi.org/10.2174/157340610791208727
DOI https://dx.doi.org/10.2174/157340610791208727 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Screen-Printed Biosensors in Drug Analysis
Current Pharmaceutical Analysis Metabotropic Glutamate Receptors and Interacting Proteins: Evolving Drug Targets
Current Drug Targets Serotonin as a Modulator of Glutamate- and GABA-Mediated Neurotransmission: Implications in Physiological Functions and in Pathology
Current Neuropharmacology Brain Adaptation to Stressful Stimuli: A New Perspective on Potential Therapeutic Approaches Based on BDNF and NMDA Receptors
CNS & Neurological Disorders - Drug Targets The GABAA-BZR Complex as Target for the Development of Anxiolytic Drugs
Current Topics in Medicinal Chemistry Drug Delivery Across the Blood-Brain Barrier
Current Nanoscience Is Adult Hippocampal Neurogenesis Really Relevant for the Treatment of Psychiatric Disorders?
Current Neuropharmacology Propolis Extract Regulates microRNA Expression in Glioblastoma and Brain Cancer Stem Cells
Anti-Cancer Agents in Medicinal Chemistry An Overview on Global Trends in Nanotechnological Approaches for Alzheimer Therapy
Current Drug Metabolism Regulation of Self-Reactive T Cells by Human Immunoglobulins- Implications for Multiple Sclerosis Therapy
Current Pharmaceutical Design Molecular Mechanisms of Cytochrome P450 Induction: Potential for Drug-Drug Interactions
Current Protein & Peptide Science Editorial [Hot topic: The Urokinase Receptor System as Strategic Therapeutic Target: Challenges for the 21st Century (Executive Guest Editor: Bernard Degryse)]
Current Pharmaceutical Design Pathogens and Chronic or Long-Term Neurologic Disorders
Cardiovascular & Hematological Disorders-Drug Targets New Route to Synthesize Fluorine Substituted Lamotrigine Drug Analogues as an Anti-Inflammatory Agent
Current Organic Synthesis Non-Selective Cation Channel Blockers: Potential Use in Nervous System Basic Research and Therapeutics
Mini-Reviews in Medicinal Chemistry Diacylglycerol Kinases as Emerging Potential Drug Targets for a Variety of Diseases
Current Drug Targets Treatment Options in Alzheimer´s Disease: The GABA Story
Current Pharmaceutical Design Intrahippocampal Amyloid-β (1-40) Injections Injure Medial Septal Neurons in Rats
Current Alzheimer Research Contrasting Roles of the Galectin-3 in the Schizophrenia Onset, Clinical Presentation, and Somatic Comorbidity
Current Topics in Medicinal Chemistry Biological Drugs in Guillain-Barré Syndrome: An Update
Current Neuropharmacology